The Phase 3 trial for batoclimab in participants with active Thyroid Eye Disease reached primary completion on November 2, 2025. This study, which enrolled 114 participants, aimed to evaluate the efficacy of batoclimab compared to placebo in addressing this autoimmune condition.
Background
Batoclimab is being investigated as a potential treatment for Thyroid Eye Disease (TED). TED is an autoimmune condition that affects the tissues around the eyes, often leading to inflammation, swelling, and proptosis (eye bulging). The development of treatments like batoclimab aims to address the underlying mechanisms of this debilitating condition, offering new therapeutic avenues for patients.
Trial design
The trial, identified as NCT05517421, was a Phase 3 study designed to assess batoclimab in participants with active Thyroid Eye Disease. It enrolled 114 participants. The study's objective was to evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo. The primary focus of evaluation for this study was on the proptosis responder rate at Week 24.
What this means
The primary completion of this Phase 3 trial for batoclimab indicates that data collection for the study's primary objectives has concluded. This marks a significant step towards the potential availability of results, which will provide insights into batoclimab's efficacy and safety profile in treating active Thyroid Eye Disease. Clinicians and patients await these findings to understand the potential role of batoclimab in managing this challenging condition.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT05517421, titled "Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease," was updated to reflect primary completion on November 2, 2025, on clinicaltrials.gov.